ArticleJournal of family medicine and primary care2025
Managing epilepsy in older adults: A Saudi Arabian perspective on drug selection.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Characteristics, Treatment Patterns, and Drug-Resistant Epilepsy Among Emirati Adults with Epilepsy.Neurology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Epilepsy is increasingly prevalent among older adults, with stroke, neurodegenerative diseases, and brain tumors being the most common etiologies. Treatment in this population is complicated by age-related physiological changes and the risk of polypharmacy, requiring careful selection of antiseizure medications (ASMs). Methods: A retrospective chart review was conducted for patients aged 60 years and above who were newly diagnosed with epilepsy and attended the neurology clinics at King Abdulaziz University Hospital, Jeddah, Saudi Arabia, between January 2015 and December 2020. Demographic and clinical data, including ASM prescriptions and tolerability, were analyzed using SPSS version 20 (SPSS Statistics developed by IBM for data management, Armonk, New York, United States of America). Results: A total of 82 patients were included (mean age: 69 years; 58.5% male). Levetiracetam (LEV) was the most commonly prescribed ASM (69.5%), followed by phenytoin (37.8%). Valproic acid, carbamazepine, lamotrigine (LTG), and topiramate were used to a lesser extent. Prescription patterns did not significantly differ by age group or gender. LEV was favored due to its favorable safety profile and minimal drug interactions. Conclusion: LEV is the most preferred ASM for elderly patients with epilepsy in Jeddah, likely due to its efficacy, tolerability, and low interaction risk. Individualized treatment strategies remain essential, given the complex comorbidities and pharmacological considerations in this age group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.